Abstract
Medical management of atherosclerosis is based on the control of its risk factors (dyslipidemia, hypertension, family history, and smoking) and predisposing conditions (e.g., the metabolic syndrome and diabetes), but no drugs specifically target the arterial plaque. The search is on for therapeutic interventions that can act as antiatherosclerosis agents, selectively targeting one or more of the features of the atheroma, such as endothelial dysfunction, inflammation, or foam-cell formation.Approaches that target arterial plaque through the use of acyl–coenzyme A:cholesterol acyltransferase (ACAT) inhibitors have been investigated experimentally for two decades. ACAT inhibitors interfere with intracellular cholesterol transport within plaque macrophages and . . .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
